Daxdilimab is under clinical development by Amgen and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to GlobalData, Phase II drugs for Idiopathic Inflammatory Myopathy (IIM) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Daxdilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daxdilimab overview
Daxdilimab (VIB-7734, MEDI-7734) is under development for the treatment of type I interferon-mediated autoimmune diseases including cutaneous lupus erythematosus, dermatomyositis, anti-synthetase inflammatory myositis, and alopecia areata. It is administered through intravenous and subcutaneous route. It is a monoclonal antibody that binds to an extracellular domain of human ILT7. The drug candidate is developed based on dendritic cell platform.
It was also under development for systemic lupus erythematosus, COVID-19-related pneumonia, lupus nephritis and acute lung injury and polymyositis, Sjogren's syndrome, systemic sclerosis.
Amgen overview
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Daxdilimab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
